HRP20000494B1 - Farmaceutski aktivni morfolinol - Google Patents

Farmaceutski aktivni morfolinol

Info

Publication number
HRP20000494B1
HRP20000494B1 HR20000494A HRP20000494A HRP20000494B1 HR P20000494 B1 HRP20000494 B1 HR P20000494B1 HR 20000494 A HR20000494 A HR 20000494A HR P20000494 A HRP20000494 A HR P20000494A HR P20000494 B1 HRP20000494 B1 HR P20000494B1
Authority
HR
Croatia
Prior art keywords
pharmaceutically active
morpholinol
pharmaceutically acceptable
active morpholinol
solvates
Prior art date
Application number
HR20000494A
Other languages
English (en)
Inventor
Frederick Morgan Phillip
Lee Musso David
Joseph Partridge John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20000494A2 publication Critical patent/HRP20000494A2/hr
Publication of HRP20000494B1 publication Critical patent/HRP20000494B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutski pripravak, naznačen time, da sadrži (+)-(2S,3S)-2-(3-klorfenil)-3,5,5-trimetil-2-morfolinol ili farmaceutski prihvatljivu sol ili solvatistog spoja zajedno s jednim ili više farmaceutski prihvatljivih nosača, diluensa ili ekscipijensa.Patent sadrži još 6 patentnih zahtjeva.
HR20000494A 1998-01-21 2000-07-21 Farmaceutski aktivni morfolinol HRP20000494B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (2)

Publication Number Publication Date
HRP20000494A2 HRP20000494A2 (en) 2000-12-31
HRP20000494B1 true HRP20000494B1 (hr) 2009-02-28

Family

ID=26312986

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20000494A HRP20000494B1 (hr) 1998-01-21 2000-07-21 Farmaceutski aktivni morfolinol
HR20051024A HRP20051024A2 (hr) 1998-01-21 2005-12-29 Farmaceutski aktivni morfolinol

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20051024A HRP20051024A2 (hr) 1998-01-21 2005-12-29 Farmaceutski aktivni morfolinol

Country Status (30)

Country Link
US (2) US6274579B1 (hr)
EP (2) EP1047428B1 (hr)
JP (1) JP2002501025A (hr)
KR (1) KR100568063B1 (hr)
CN (2) CN1203858C (hr)
AP (1) AP1229A (hr)
AT (1) ATE365042T1 (hr)
AU (1) AU755536B2 (hr)
BR (1) BR9907203A (hr)
CA (1) CA2318268A1 (hr)
CY (1) CY1106828T1 (hr)
DE (1) DE69936335T2 (hr)
DK (1) DK1047428T3 (hr)
EA (1) EA002410B1 (hr)
EE (1) EE04452B1 (hr)
ES (1) ES2288012T3 (hr)
HR (2) HRP20000494B1 (hr)
HU (1) HUP0100900A3 (hr)
ID (1) ID26334A (hr)
IL (2) IL161942A0 (hr)
IS (1) IS2494B (hr)
NO (2) NO326878B1 (hr)
NZ (3) NZ529316A (hr)
PL (1) PL193622B1 (hr)
PT (1) PT1047428E (hr)
SG (1) SG115489A1 (hr)
SK (1) SK10912000A3 (hr)
TR (1) TR200002126T2 (hr)
WO (1) WO1999037305A1 (hr)
YU (1) YU67102A (hr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501891A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの医薬用途
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101072885B1 (ko) * 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
ATE413882T1 (de) * 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
JP2007509856A (ja) * 2003-10-27 2007-04-19 スミスクライン ビーチャム コーポレーション （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
CA2553207A1 (en) 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
EP1968603A4 (en) * 2006-01-03 2013-01-16 Algebra Inc THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
WO2011146821A2 (en) 2010-05-21 2011-11-24 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
AU2011255276B2 (en) 2010-05-21 2016-09-22 Research Triangle Institute Phenylmorpholines and analogues thereof
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
AU755536B2 (en) 2002-12-12
NO326878B1 (no) 2009-03-09
SG115489A1 (en) 2005-10-28
US20020019396A1 (en) 2002-02-14
CN1203858C (zh) 2005-06-01
SK10912000A3 (sk) 2001-04-09
PL342012A1 (en) 2001-05-07
NO20083529L (no) 2000-09-19
WO1999037305A1 (en) 1999-07-29
PT1047428E (pt) 2007-09-07
IL161942A0 (en) 2005-11-20
EE200000438A (et) 2001-12-17
EA002410B1 (ru) 2002-04-25
ATE365042T1 (de) 2007-07-15
US6391875B2 (en) 2002-05-21
US6274579B1 (en) 2001-08-14
YU67102A (sh) 2004-12-31
PL193622B1 (pl) 2007-02-28
IL137346A0 (en) 2001-07-24
HUP0100900A3 (en) 2002-08-28
HUP0100900A2 (hu) 2002-05-29
TR200002126T2 (tr) 2000-12-21
HRP20051024A2 (hr) 2006-04-30
NZ529316A (en) 2004-05-28
ID26334A (id) 2000-12-14
EE04452B1 (et) 2005-04-15
EP1047428A4 (en) 2001-12-19
HRP20000494A2 (en) 2000-12-31
DK1047428T3 (da) 2007-10-08
CN1528753A (zh) 2004-09-15
NZ505809A (en) 2002-09-27
KR100568063B1 (ko) 2006-04-07
KR20010034285A (ko) 2001-04-25
CN1294513A (zh) 2001-05-09
JP2002501025A (ja) 2002-01-15
DE69936335D1 (de) 2007-08-02
BR9907203A (pt) 2000-10-17
EP1047428B1 (en) 2007-06-20
AP1229A (en) 2003-12-04
EP1047428A1 (en) 2000-11-02
NO20003721D0 (no) 2000-07-20
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
EA200000691A1 (ru) 2001-04-23
IS5568A (is) 2000-07-20
NO20003721L (no) 2000-09-19
EP1829544A1 (en) 2007-09-05
AP2000001869A0 (en) 2000-09-30
ES2288012T3 (es) 2007-12-16
CY1106828T1 (el) 2012-05-23
NZ520349A (en) 2004-02-27
AU2328099A (en) 1999-08-09
CN1255389C (zh) 2006-05-10
DE69936335T2 (de) 2008-02-28

Similar Documents

Publication Publication Date Title
HRP20000494B1 (hr) Farmaceutski aktivni morfolinol
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
NO2011025I1 (no) Telavancin, eller et farmasøytisk aksseptabelt salt derav, herunder inkludert telavancin hydroklorid
FI950947A0 (fi) Oraalisesti annettavat farmaseuttiset formulaatiot
DE60039291D1 (de) Camptothecinanaloge und deren zubereitungsmethoden
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
CA2326222A1 (en) Medicinal compositions
HRP20000181B1 (en) 2-methyl-thieno-benzodiazepine formulation
TR199901077A3 (tr) Ispençiyari formülasyonlar.
RS50352B (sr) Monosupstituisane 3-propil gama-aminobuterne kiseline
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
DE69915487D1 (de) Erythromycin-derivate mit antibiotischer wirkung
DZ1576A1 (fr) Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
HRP20000400B1 (hr) Transmukozni pripravci levosimendana
EP1073447A4 (en) N1-MODIFIED GLYCOPEPTIDES
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
FR2668697B1 (fr) Dissecteur, notamment pour chirurgie endoscopique.
SE9701438D0 (sv) A new process
ATE491709T1 (de) Pyrrolidinohydrochinazoline
MA26677A1 (fr) Medicaments antiparkinsoniens.
DK1086695T3 (da) Antivirale præparater omfattende yohimbin som aktivt princip
RU2001109481A (ru) Антиангинальное средство

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120118

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20130121